CA2301162A1 - Preparation contraceptive orale comportant une premiere phase a base de progestine/oestrogene et une seconde phase a base de progestine - Google Patents
Preparation contraceptive orale comportant une premiere phase a base de progestine/oestrogene et une seconde phase a base de progestine Download PDFInfo
- Publication number
- CA2301162A1 CA2301162A1 CA002301162A CA2301162A CA2301162A1 CA 2301162 A1 CA2301162 A1 CA 2301162A1 CA 002301162 A CA002301162 A CA 002301162A CA 2301162 A CA2301162 A CA 2301162A CA 2301162 A1 CA2301162 A1 CA 2301162A1
- Authority
- CA
- Canada
- Prior art keywords
- days
- combination
- levonorgestrel
- administered
- progestin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000583 progesterone congener Substances 0.000 title claims abstract description 79
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims abstract description 73
- 229940011871 estrogen Drugs 0.000 title claims abstract description 67
- 239000000262 estrogen Substances 0.000 title claims abstract description 67
- 229940127234 oral contraceptive Drugs 0.000 title description 12
- 239000003539 oral contraceptive agent Substances 0.000 title description 12
- 238000002360 preparation method Methods 0.000 title description 4
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims abstract description 52
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims abstract description 52
- 229960002568 ethinylestradiol Drugs 0.000 claims abstract description 52
- 230000027758 ovulation cycle Effects 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 19
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 81
- 229960004400 levonorgestrel Drugs 0.000 claims description 75
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims description 32
- 229960004976 desogestrel Drugs 0.000 claims description 32
- 239000003433 contraceptive agent Substances 0.000 claims description 19
- 230000002254 contraceptive effect Effects 0.000 claims description 17
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims description 11
- 229960005352 gestodene Drugs 0.000 claims description 11
- 229940053934 norethindrone Drugs 0.000 claims description 10
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 10
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims description 9
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims description 7
- 229960000978 cyproterone acetate Drugs 0.000 claims description 6
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 6
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 claims description 6
- 229960001390 mestranol Drugs 0.000 claims description 6
- 229960000417 norgestimate Drugs 0.000 claims description 6
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 5
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 5
- 229940035811 conjugated estrogen Drugs 0.000 claims description 5
- 229960004845 drospirenone Drugs 0.000 claims description 5
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims description 5
- 230000001076 estrogenic effect Effects 0.000 claims description 5
- 229960001652 norethindrone acetate Drugs 0.000 claims description 5
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 4
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 4
- 229960003309 dienogest Drugs 0.000 claims description 4
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims description 4
- 229960003399 estrone Drugs 0.000 claims description 4
- ZLLOIFNEEWYATC-XMUHMHRVSA-N osaterone Chemical compound C1=C(Cl)C2=CC(=O)OC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 ZLLOIFNEEWYATC-XMUHMHRVSA-N 0.000 claims description 4
- 229950006466 osaterone Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- JUNDJWOLDSCTFK-MTZCLOFQSA-N trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 claims description 4
- 229950008546 trimegestone Drugs 0.000 claims description 4
- ORKBYCQJWQBPFG-WOMZHKBXSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ORKBYCQJWQBPFG-WOMZHKBXSA-N 0.000 claims description 3
- 229960002826 levonorgestrel and ethinylestradiol Drugs 0.000 claims description 3
- 229960005309 estradiol Drugs 0.000 description 27
- 230000000694 effects Effects 0.000 description 8
- 239000006187 pill Substances 0.000 description 8
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000016087 ovulation Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 3
- 210000004914 menses Anatomy 0.000 description 3
- 230000001072 progestational effect Effects 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 2
- 101000605827 Homo sapiens Pinin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102100038374 Pinin Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- METQSPRSQINEEU-OLKMEILKSA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3C3C4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-OLKMEILKSA-N 0.000 description 2
- 229960004766 estradiol valerate Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000009424 thromboembolic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VNFVKWMKVDOSKT-LREBCSMRSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;piperazine Chemical class C1CNCCN1.OC(=O)[C@H](O)[C@@H](O)C(O)=O VNFVKWMKVDOSKT-LREBCSMRSA-N 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 101150054830 S100A6 gene Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010047998 Withdrawal bleed Diseases 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 229960001616 chlormadinone acetate Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 231100000546 inhibition of ovulation Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- LFULEKSKNZEWOE-UHFFFAOYSA-N propanil Chemical compound CCC(=O)NC1=CC=C(Cl)C(Cl)=C1 LFULEKSKNZEWOE-UHFFFAOYSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000015887 sperm entry Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cette invention concerne un procédé de contraception consistant à administrer à une femme en âge de procréer, pendant 23-25 jours à partir du premier jour du cycle menstruel, une combinaison de progestine à une posologie quotidienne équivalente à 30-150 µg de lévonorgestrel et d'un oestrogène à une posologie quotidienne équivalente à 10-20 µg d'éthinyloestradiol, puis à administrer pendant 3-5 jours une progestine à une posologie quotidienne équivalente à 10-100 µg de lévonorgestrel, la durée totale d'administration étant de 28 jours par cycle menstruel.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92853097A | 1997-09-12 | 1997-09-12 | |
| US08/928,530 | 1997-09-12 | ||
| PCT/US1998/018850 WO1999013882A1 (fr) | 1997-09-12 | 1998-09-09 | Preparation contraceptive orale comportant une premiere phase a base de progestine/oestrogene et une seconde phase a base de progestine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2301162A1 true CA2301162A1 (fr) | 1999-03-25 |
Family
ID=25456367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002301162A Abandoned CA2301162A1 (fr) | 1997-09-12 | 1998-09-09 | Preparation contraceptive orale comportant une premiere phase a base de progestine/oestrogene et une seconde phase a base de progestine |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1011681A1 (fr) |
| JP (1) | JP2001516720A (fr) |
| CN (1) | CN1270521A (fr) |
| AU (1) | AU759925B2 (fr) |
| CA (1) | CA2301162A1 (fr) |
| WO (1) | WO1999013882A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8338396B2 (en) | 2001-12-05 | 2012-12-25 | Teva Women's Health, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| US8415332B2 (en) | 2004-10-07 | 2013-04-09 | TEVA Woman's Health, Inc. | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
| CN116370599A (zh) * | 2023-03-20 | 2023-07-04 | 佛山科学技术学院 | 抗菌肽pg-1在促进卵巢颗粒细胞分泌激素中的应用 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001030355A1 (fr) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation |
| FR2754179B1 (fr) | 1996-10-08 | 1998-12-24 | Theramex | Nouvelle composition hormononale et son utilisation |
| WO2003041719A1 (fr) * | 2001-11-15 | 2003-05-22 | Pantarhei Bioscience B.V. | Procede de contraception chez des femelles de mammiferes, et kit pharmaceutique correspondant |
| JP2005519962A (ja) * | 2002-03-11 | 2005-07-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | スルファターゼを阻害する継続的プロゲストゲン避妊レジメン |
| CN1652799A (zh) * | 2002-03-11 | 2005-08-10 | 詹森药业有限公司 | 只用抑制硫酸酯酶的孕激素的避孕给药方案 |
| AU2003218119A1 (en) * | 2002-03-11 | 2003-09-29 | Janssen Pharmaceutica N.V. | Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens |
| CN104546870B (zh) * | 2015-01-27 | 2018-01-12 | 唐凡兰 | 一种避孕药 |
| EP4134082A1 (fr) | 2021-08-12 | 2023-02-15 | Chemo Research, S.L. | Procédé de traitement de l'endométriose et de fourniture de contraception efficace |
| WO2025172590A1 (fr) | 2024-02-16 | 2025-08-21 | Pandora Endocrine Innovation B.V. | Kit contraceptif comprenant des unités posologiques orales contenant de la déhydroépiandrostérone |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368373A1 (fr) * | 1988-10-13 | 1990-05-16 | Akzo Nobel N.V. | Préparation contraceptive multiphase |
| DE19549264A1 (de) * | 1995-12-23 | 1997-06-26 | Schering Ag | Verfahren und Kit zur Kontrazeption |
-
1998
- 1998-09-09 CN CN98809067A patent/CN1270521A/zh active Pending
- 1998-09-09 WO PCT/US1998/018850 patent/WO1999013882A1/fr not_active Ceased
- 1998-09-09 CA CA002301162A patent/CA2301162A1/fr not_active Abandoned
- 1998-09-09 JP JP2000511503A patent/JP2001516720A/ja active Pending
- 1998-09-09 EP EP98944837A patent/EP1011681A1/fr not_active Withdrawn
- 1998-09-09 AU AU92286/98A patent/AU759925B2/en not_active Ceased
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8338396B2 (en) | 2001-12-05 | 2012-12-25 | Teva Women's Health, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| US8680084B2 (en) | 2001-12-05 | 2014-03-25 | Teva Women's Health, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| US8415332B2 (en) | 2004-10-07 | 2013-04-09 | TEVA Woman's Health, Inc. | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
| US8450299B2 (en) | 2004-10-07 | 2013-05-28 | Teva Womans's Health, Inc. | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
| CN116370599A (zh) * | 2023-03-20 | 2023-07-04 | 佛山科学技术学院 | 抗菌肽pg-1在促进卵巢颗粒细胞分泌激素中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1270521A (zh) | 2000-10-18 |
| AU9228698A (en) | 1999-04-05 |
| EP1011681A1 (fr) | 2000-06-28 |
| JP2001516720A (ja) | 2001-10-02 |
| WO1999013882A1 (fr) | 1999-03-25 |
| AU759925B2 (en) | 2003-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5858405A (en) | Oral contraceptive | |
| US5888543A (en) | Oral contraceptives | |
| US5747480A (en) | Oral contraceptive | |
| EP0956024B1 (fr) | Methode de contraception orale monophasique et kit comprenant une association de progestine et d'oestrogene | |
| US6479475B1 (en) | Oral contraceptive | |
| US20010020015A1 (en) | Combination progestin oral contraceptive regimen | |
| EP0917466B1 (fr) | Contraceptif oral | |
| WO1998004246A2 (fr) | Contraceptif oral | |
| US6451778B1 (en) | Oral contraceptive | |
| AU759925B2 (en) | Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin | |
| EP0921804B1 (fr) | Methode contraceptive orale a deux phases et kit comportant une combinaison d'une progestine et d'un oestrogene | |
| WO1998004267A1 (fr) | Contraceptif oral a base de progestine et d'oestrogene | |
| WO1998004266A1 (fr) | Contraceptif oral | |
| WO1997041868A1 (fr) | Contraceptif oral | |
| WO1997041870A1 (fr) | Contraceptif oral | |
| WO1997041869A1 (fr) | Contraceptif oral | |
| WO1997041871A1 (fr) | Contraceptif oral | |
| WO1997041872A1 (fr) | Contraceptif oral | |
| HK1022843B (en) | Monophasic oral contraceptive method and kit comprising a combination of progestin and estrogen | |
| MXPA99000801A (en) | Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen | |
| MXPA99000883A (en) | Oral contraceptive |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |